Introduction
Errors in drug selection and drug use are among the common adverse events in hospitals (1, 2) . The European Board of Anesthesiology and the European Society of Anesthesiology have stated that drug errors reduce patient safety, but that they can be prevented (3, 4) . Most anesthesia workers (AW), who are responsible for completing all steps of drug administration, encounter drug errors in the complex and rapidly changing environment of the operating theater (1, 5) . Each drug should be used at the right time, in the right dose and right order during the perioperative period. It is very easy to confuse the drugs. Color labels used for specific drugs reduce drug administration errors (DAE) and the standard syringe label (SSL) improves patient safety (6, 7) . Most anesthesiologists suggest that the color of the label is an important factor for identifying a drug (8, 9) .
The use of handwritten labels is a problem because it is easy to make mistakes either in writing or reading them. Therefore, the current drug syringe label situation has been documented as one of the primary causes of error. The International Organization for Standardization (ISO) and anesthesiology societies have guidelines focused on the development of prepared syringe labels for dosage, volume, dilution and color coding, and recommend standardization of syringe labeling (10, 11) .
In our study, it was aimed to report the attitudes of AW (resident, specialist, lecturer, technician) towards labeling, to emphasize the importance of drug labeling in drug errors and to contribute to safe anesthesia practices by raising awareness about standardization.
Methods
This cross-sectional study was conducted between September 2016 and January 2017 with the permission of the Zonguldak Bülent Ecevit University Local Ethics Committee (decision no: 2016/10, date: 24.08.2016). Informed consent wasn't obtained because it was a survey study. Data Collection Methods: AW in our country were contacted through the Turkish Anesthesiology and Reanimation Society (TARD), which have approximately 4000 members. The questionnaire form was created by reviewing the studies in the literature (Appendix). The questionnaire was sent with a text providing information about the subject. The data were obtained from the participants through a web-based questionnaire data form. The questionnaire was sent twice in 4-week intervals to each member of TARD and to technicians whose email addresses were known, and those who had participated previously were reminded not to participate again. The identities of the participants were kept confidential.
Questionnaire Form:
The questionnaire consisted of four sections. The first section contained data on the demographic characteristics, duties, institutions and working years of the workers. The second section inquired about the experiences of drug errors, potential causes, and one or more factors for each event. The clinical outcomes of drug errors were reported. The third section included the ideas of AW on label and package characteristics, SSL awareness, the rate of colorcoded self-adhesive label use, and data on standardization of labels. The last section inquired about the rate of notifying drug errors and informing the patients about the event, the reasons for not notifying errors, whether AW were punished for the errors or not, whether they notified the errors to a national reporting program, and whether or not they asked the protocol from TARD for labeling and recommendations for prevention of drug errors. Except for the first section, multiple-choice questions in the other sections can be marked with multiple choices.
Statistical Analysis
Frequency (%) of the answers of the volunteering participants was determined.
Results
A total of 189 questionnaires were evaluated. Demographic characteristics of the participants are presented in Table 1 . A total of 325 DAEs were described and are shown in Table 2 . Fifty-two point nine percent (n=100) of the participants stated that they administered the incorrect drug during anesthesia induction at least once. Table 2 also displays the frequency of DAE observation. Results of DAE are explained in Table 3 . When participants were asked to state the importance of some of the features they used to identify the syringe or the label, the label color of the vial and the color of the vial were found to be "extremely important" at rates of 42.3% and 32.8%, and the font size for prepared syringes was found to be "extremely important" at a rate of 44.4%. Of the participants, 49.2% (n=93) were aware of SSL. While 66.7% of these participants stated that they used color-coded self-adhesive labels, 46.2% stated that they did not know which standards these labels met.
Color-coded self-adhesive labels (92.9%), standardized labeling system for vials (97.3%) and the prepared syringes (87.8%) were suggested by AW to be effective in reducing DAE. Of the participants, 89.9% (n=170) stated that they did not know DAE. Of the participants who notified DAE, 56.2% (n=16) stated that they reported the error to the chief of the clinic, but they did not report it to the official website of an institution, and three participants were found not to respond to this question. The reasons for not reporting DAE are presented in Table 4 . The errors were not reported to the patients at a rate of 94.7% (n=179), and the rate of being not punished was 99.4% (n=182). Of the responders, 90.5% (n=171) stated that they would notify the DAE if there were a single notification center and 95.8% stated that they wanted TARD to develop a protocol for labeling. AW (n=100) stated that DAE could be prevented through standard labeling procedures (47%), attention and care (23%), training (21%) and producing the vials in different sizes and colors (9%).
Discussion
Our study revealed that most AW had at least one or more DAE experience, and that 54.3% of the errors were clinically insignificant.
Most of the participants stated that color was the most important feature in the identification of drugs. We determined the rate of SSL awareness as 49.2% and the use of color-coded self-adhesive labels as 66.7%; however, 46.2% of the participants did not know the standards required for the labels.
AW can make mistakes with loss of concentration despite problem solving, decision-making and application skills. DAEs may arise at any stage of the therapeutic procedure, and its incidence has been reported to be between 1-10%, and this rate has been reported not to significantly change over a period of more than 15 years (8, (12) (13) (14) (15) (16) (17) (18) . In two questionnaire studies, the rate of observation of one or more DAEs by AW was %61.7 and %91.8 (8, 19) . We determined that 52.9% of the participants experienced at least one DAE during anesthesia applications. We consider that AW may be reluctant to report all errors, and that the number of the reported errors is small given the large number of drugs used in anesthesia. Prospective studies are required to determine the prevalence of DAE, and our findings may lead to awareness of AW.
There are many reasons for DAEs in anesthesia applications. The most common causes of perioperative DAE include injection of the incorrect drug, administration of an excessive dose, incorrect route of administration and negligence. Inadequate follow-up of treatment or side effects, inadequate standardization of labels and protocols, carelessness, excessive workload, inappropriate working hours, poor communication, impetuousness, fatigue, medical and paramedical staff-related problems were also reported to contribute to DAE (4, 8, 14, (17) (18) (19) (20) (21) (22) (23) (24) . In addition, incorrect or missing drug labels, interchange of syringe labels and vials, unlabeled syringes, and failure to estimate the dose of the drug were also reported (5, 7, 8, 12, 22) . There are studies reporting that errors arise from interchange of the syringe (44.4%-70.4%) and incorrect definition of the label (46.8%) (5, 8, 18, 22) . In our study, consistent with the literature, we found that errors were caused by many reasons such as incorrect drug and dose.
There are various measures for the prevention of DAEs in anesthesia as they are preventable and may be potentially fatal (24, 25) . Regarding the recommendations for preventing DAEs, Russel W. (26) recommended different color codes for the syringes according to the drug types. The Japanese Society of Anesthesiology reported that outcomes of the series of preventive measures in preventing DAE were not satisfactory despite the current measures; and that the current syringe labels are among the main causes of DAE (27) . The recommendations also include the use of international color codes for labeling and color syringes, and production of different looking drugs by drug companies (17, 22, 28) .
Considering the safety, designing labels is a step toward developing a safer system. Canada developed the first standardization for labeling vials and prepared syringes (14) . Many countries use a standard color code for anesthetic drug syringes. Many studies have reported that the rate of SSL use is between 19% and 96%, while some authors report that they have developed their standards, and some others report that they use the color codes of ISO standards (3, 8, 9, 17, (28) (29) (30) . Orser et al. (8) reported the rate of awareness of anesthetists regarding self-adhesive color-coded labels as 86.5% in their questionnaire study, and 84% of the participants in this study stated that drug label standards would reduce the incidence of DAE. In our study, consistent with the literature, we determined that the standard labeling procedure was an important factor in the prevention of DAE. We also determined that the rate of awareness and use of SSL in our study was lower than European data. No mandatory regulations are available for labeling standardization in our country, and our study revealed that AW supported labeling standards. We also determined that AW did not know the standards from which the color-coded labels were prepared and they suggested that TARD should It has been reported that specific protocols should be developed for prevention of DAE, trainings should be scheduled, routines for equipment care and control should be improved, and that more manpower and communication should be provided (22) . We think that DAE may be reduced with similar measures.
Some DAE may lead to severe morbidity and even mortality, although most of them are not significant (12, 21) . The reason for minor morbidities caused by DAE in anesthesia include early recognition of the error, rapid physiological changes caused by drugs and special follow-up methods in critical events. There are also studies reporting mortality (5, 8, 12, 14, 21, 22) . We detected that the adverse events in our study were consistent with the literature and most of them resulted in minor morbidities, with only four deaths with unknown origin.
Orser et al. (8) reported that 60.1% of DAEs in anesthesia applications were not reported due to being considered as insignificant. The participants also reported that they did not know where to and whom to report the errors. In the same study, almost half of the participants reported that they would report the errors to a national notifying program. It is also known that DAEs are not reported individually or by the department (2, 17) . In our questionnaire, we observed that 89.9% of the errors were not reported and, if reported, they were mostly reported to the chief of the department. A Safety Notifying System (www.kalite.saglik.gov.tr) is available in our country; however, most AW are unaware of this website and we consider that critical errors should be reported in accordance with the relevant rules.
One limitation of our study is that our study was a web-based questionnaire study and the number of responders was less than similar studies in the literature. Therefore, the results may not reflect the attitudes of all AW. Besides, the prevalence cannot be determined, as the details of the errors experienced years ago could have been forgotten.
The results of the present study may in general present the preliminary data for the development of quality standards in our country. We observed that most AW participating in the study did not use SSL, and that more than half experienced at least one DAE, and that these were caused by mislabeling.
Conclusion
In our study, AW stated that developing and standardizing the vial labels, scheduling trainings, paying care and attention were important for the prevention of labeling-related errors. In addition, DAEs were not frequently reported. Anesthetists and managers should be aware of this problem. Notification mechanisms should be utilized for the prevention of potential events and future events, and determination of the measures. Prospective randomized studies are required for investigating strategies to reduce DAEs. The use of error notification systems would develop a safer patient culture.
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Attitude and Behavior of Anesthesia Workers about Labelling in Anesthetic Drug Administration
Dear colleagues,
The following questions were prepared with the aim of determining attitudes and behaviors about labeling in anesthetic drug administration. Answering the questions is optional. You will not be prompted to enter your first name or last name on the forms. Confidentiality will be ensured by researchers. 
